DNA ploidy in epithelial ovarian cancer: An independent prognostic factor;DNA-ploiditet ved epitelial ovarialkreft - En uavhengig prognostisk faktor

Tidsskrift for den Norske Laegeforening

Volumn 120, Issue 1, 2000, Pages 43-49

  Tropé, Claes G ^a   Abeler, Vera ^a   Baekelandt, Mark ^a   Kærn, Janne ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; CANCER STAGING; CARCINOMA; CELL CYCLE S PHASE; FEMALE; GENETICS; HUMAN; MIDDLE AGED; MORTALITY; NORWAY; OVARY TUMOR; PATHOLOGY; PLOIDY; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; CARCINOMA; DNA, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NORWAY; OVARIAN NEOPLASMS; PLOIDIES; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; S PHASE; SURVIVAL RATE;

EID: 0034627567     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Litteratur 1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594-606.
2. Tomatis L, Aito A, Day N, Heseltine E, Kaldor J, Meller AB et al. Cancer: causes, occurrence and control. Lyon: International Agency for Research on Cancer, 1990.
3. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993; 55: 891-903.
4. Petterson F. Annual report on the results of treatment in gynecologic cancer. Stockholm: Radiumhemmet, 1995.
5. Balvert LH, Coebergh JW, Hop WC, Brolmann HA, Crommelin M, van-Wijck DJ et al. Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study. Gynecol Oncol 1991; 42: 3-8.
6. Haybittle JL, Kingsley PE. Long-term survival experience of female patients with genital cancer. Br J Cancer 1988; 57: 322-5.
7. Piver M. Ovarian karsinoma: a decade of progress. Cancer 1994; 54: 2706-15.
8. Neijt JP, ten-Bokkel-Huinink WW, van-der-Burg ME, van-Oosterom AT, Willemse PH, Vermorken JB et al. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991; 27: 1367-72.
9. Brinkhuis M. Advanced ovarian cancer quantitative pathologic features grading and prognosis. Amsterdam: Free University, 1995.
10. Hakes T. Prognostic factors in ovarian cancer. I: Markman M, Hoskins W, red. Cancer of the ovary. New York: Raven Press, 1993: 115-25.
11. Kaern J, Trope CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 1993; 71: 1810-20.
12. Einhorn N, Nilsson B, Sjovall K. Factors influencing survival in carcinoma of the ovary. Study from a welldefined Swedish population. Cancer 1985; 55: 2019-25.
13. Aure JC, Hoeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol 1971; 37: 1-9.
14. Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990; 75: 263-73.
15. Klaassen D, Shelley W, Starreveld A, Kirk M, Boyes D, Gerulath A et al. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report. J Clin Oncol 1988; 6: 1254-63.
16. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990; 322: 1021-7.
17. Krag KJ, Canellos GP, Griffiths CT, Knapp RC, Parker LM, Welch WR et al. Predictive factors for long-term survival in patients with advanced ovarian cancer. Gynecol Oncol 1989; 34: 88-93.
18. Friedlander ML, Dembo AJ. Prognostic factors in ovarian cancer. Semin Oncol 1991; 18: 205-12.
19. Marsoni S, Torri V, Valsecchi MG, Belloni C, Bianchi U, Bolis G et al. Prognostic factors in advanced epithelial ovarian cancer (Gruppo Inter-regionale Cooperativo di Oncologia Ginecologica (GICOG)). Br J Cancer 1990; 62: 444-50.
20. Advanced ovarian cancer trialists group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. BMJ 1991; 303: 884-92.
21. Iversen OE, Laerum OD. Ploidy disturbances in endometrial and ovarian carcinomas. A review. Anal Quant Cytol Histol 1985; 7: 327-36.
22. Iversen OE. Cellular DNA and steroid receptors in endometrial and ovarian carcinomas: clinical and prognostic importance. Doktoravhandling. Bergen: Gades Institutt og Haukeland Sykehus, 1986.
23. Kaern J. DNA ploidy in epithelial ovarian malignancies. Prognostic value and therapeutic implications. Doktoravhandling. Oslo: Det Norske Radiumhospital, 1993.
24. Kaern J, Wetteland J, Trope CG, Farrants GW, Juhng SW, Pettersen EO et al. Comparison between flow cytometry and image cytometry in ploidy distribution assessments in gynecologic cancer. Cytometry 1992; 13: 314-21.
25. Henriksen R. Ovarian carcinogenesis. A study of markers for growth mechanisms in epithelial ovarian tumors. Doktoravhandling. Uppsala: Uppsala universitet, 1994.
26. Henriksen R, Strang P, Backstrom T, Wilander E, Tribukait B, Oberg K. Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers. Anticancer Res 1993; 14: 603-8.
27. Vergote IB, Kaern J, Abeler VM, Pettersen EO, De-Vos LN, Trope CG. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relipse. Am J Obstet Gynecol 1993; 169: 40-52.
28. Kaern J, Trope C, Kristensen G, Abeler VM, Pettersen EO. DNA ploidy, the most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer 1993; 3: 349.
29. Tropé C, Kaern J, Vergote I, Hagen B, Rosenberg P, Bertelsen K et al. Randomized trial on adjuvant carboplatin versus no treatment in stage I high risk ovarian cancer by the Nordic Ovarian Cancer Study Group (NOCOVA). Proc Am Soc Clin Oncol 1997; 16: 352.
30. Kaern J, Trope C, Kristensen G, Tveit KM, Pettersen EO. Evaluation of DNA ploidy and S-phase fraction as prognostic parameter in advanced epithelial ovarian carsinoma - a prospective study. Am J Obstet Gynecol 1994; 170: 479-87.
31. Neijt J, Wiltshaw E, Lund B. Consensus. Advanced ovarian cancer: where do we stand and where do we go. Elsinore 1993. Ann Oncol 1993; 4: 583-8.
32. Iversen OE. Prognostic value of the flow cytometric DNA index in human ovarian carcinoma. Cancer 1988; 61: 971-5.
33. Baak JP, Abeler V, Broeckaert MA. Morphometry and DNA cytometry have strong and additional prognostic value in borderline ovarian tumors with long-term follow-up. J Pathol 1995: 42: 49.
34. Kallioniemi OP, Punnonen R, Mattila J, Lehtinen M, Koivula T. Prognostic significance of DNA index, multiploidy, and S-phase fraction in ovarian cancer. Cancer 1988; 61: 334-9.
35. Klemi PJ, Joensuu H, Maenpaa J, Kiilholma P. Influence of cellular DNA content on survival in ovarian carcinoma. Obstet Gynecol 1989; 74: 200-4.
36. Haapasalo H, Atkin NB, Collan Y, Pesonen E, Paljarvi L. Tumour ploidy, morphometry, histological grading and clinical features in ovarian carcinoma: mutual relations. Anal Cell Pathol 1991; 3: 261-71.
37. Baak JP, Schipper NW, Wisse BE, Ceelen T, Bosman FT, van-Geuns H et al. The prognostic value of morphometrical features and cellular DNA content in cis-platin treated late ovarian cancer patients. Br J Cancer 1988; 57: 503-8.
38. Klemi PJ, Joensuu H, Kiilholma P, Maenpaa J. Clinical significance of abnormal nuclear DNA content in serous ovarian tumors. Cancer 1988; 62: 2005-10.
39. Lage JM, Weinberg DS, Huettner PC, Mark SD. Flow cytometric analysis of nuclear DNA content in ovarian tumors. Association of ploidy with tumor type, histologic grade, and clinical stage. Cancer 1992; 69: 2668-75.
40. Friedlander ML, Hedley DW, Swanson C, Russell P. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Oncol 1988; 6: 282-90.
41. Brescia RJ, Barakat RA, Beller U, Frederickson G, Suhrland MJ, Dubin N et al. The prognostic significance of nuclear DNA content in malignant epithelial tumors of the ovary. Cancer 1990; 65: 141-7.
42. Erba E, Ubezio P, Pepe S, Vaghi M, Marsoni S, Torri W et al. Flow cytometric analysis of DNA content in human ovarian cancers. Br J Cancer 1989; 60: 45-50.
43. Wils J, van-Geuns H, Baak J. Proposal for therapeutic approach based on prognostic factors including morphometric and flow-cytometric features in stage III-IV ovarian cancer. Cancer 1988; 61: 1920-5.
44. Gajewski WH, Fuller-AF J, Pastel LC, Flotte TJ, Bell DA. Prognostic significance of DNA content in epithelial ovarian cancer. Gynecol Oncol 1994; 53: 4-11.